{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:22:46Z","timestamp":1793744566125,"version":"4.6.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>IgA vasculitis (IgAV) is a small vessel vasculitis that is more common in childhood. Very limited evidence exists on patients who experience an atypical disease course. The aim of this study was to describe a cohort of children diagnosed with recurrent or persisting IgAV to identify any themes associated with their disease course and areas of unmet needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single centre retrospective study of children diagnosed with recurrent or persisting IgAV at Alder Hey Children\u2019s Hospital (Liverpool, UK). Clinical data, including features at presentation and during follow up, potential triggers, abnormal laboratory and histology results, treatment and outcome at last clinical review were retrospectively collected. Key themes were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 13 children met the inclusion criteria (recurrent disease, n\u2009=\u20094; persisting disease, n\u2009=\u20099). Median age at first presentation was 10.2 years [2.6\u201315.5], female:male ratio 1.2:1. Children in the atypical cohort were significantly older than a larger cohort of children who followed a non-complicated disease course (median age 5.5 years (range [0.6\u201316.7],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003)). All children re-presented with a purpuric rash (either recurring or persisting), accompanied by joint involvement in 92% of patients (12\/13). Disease-modifying anti-rheumatic drugs (DMARDs) were used in 8\/13 (62%) children. The median time from first presentation to diagnosis of atypical disease was 18.4 months [5.3-150.8] and the time from first presentation to treatment was 24.1 months [1.8\u201395.4]. Use of corticosteroids was significantly higher in children with renal involvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026). During follow up, 8\/13 (62%) children were admitted at least once, whilst 10\/13 (77%) had re-presented at least once to the emergency department. Five (38%) children were referred to psychology services and 7 (54%) children reported feelings of frustration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This series describes some characteristics of a small cohort of children with atypical IgAV. It also identifies unmet needs in children with atypical IgAV, which includes delays in diagnosis and lengthy waits for treatment, lack of high-quality evidence regarding treatment choices and a high unrecognised disease burden. Further research is needed to study this subgroup of children as evidence is lacking.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-023-00872-1","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T06:02:40Z","timestamp":1691992960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A case series on recurrent and persisting IgA vasculitis (Henoch Schonlein purpura) in children"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4954-7915","authenticated-orcid":false,"given":"Julien","family":"Marro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9276-0255","authenticated-orcid":false,"given":"Chloe","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4965-3259","authenticated-orcid":false,"given":"Clare E.","family":"Pain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-2390","authenticated-orcid":false,"given":"Louise","family":"Oni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"issue":"2","key":"872_CR1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/annrheumdis-2018-214142","volume":"78","author":"A Tracy","year":"2019","unstructured":"Tracy A, Subramanian A, Adderley NJ, Cockwell P, Ferro C, Ball S, et al. Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Sch\u00f6nlein purpura): a retrospective cohort study using routinely collected primary care data. Ann Rheum Dis. 2019;78(2):261.","journal-title":"Ann Rheum Dis"},{"key":"872_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fped.2019.00257","volume":"7","author":"L Oni","year":"2019","unstructured":"Oni L, Sampath S. Childhood IgA vasculitis (Henoch Schonlein Purpura)-Advances and knowledge gaps. Front Pediatr. 2019;7:257.","journal-title":"Front Pediatr"},{"key":"872_CR3","doi-asserted-by":"crossref","unstructured":"Song Y, Huang X, Yu G, Qiao J, Cheng J, Wu J et al. Pathogenesis of IgA Vasculitis: an Up-To-Date review. Front Immunol. 2021;12.","DOI":"10.3389\/fimmu.2021.771619"},{"issue":"5","key":"872_CR4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/art.1780400513","volume":"40","author":"R Blanco","year":"1997","unstructured":"Blanco R, Mart\u00ednez-Taboada VM, Rodr\u00edguez-Valverde V, Garc\u00eda-Fuentes M, Gonz\u00e1lez-Gay MA. Henoch-Sch\u00f6nlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis Rheum. 1997;40(5):859\u201364.","journal-title":"Arthritis Rheum"},{"key":"872_CR5","doi-asserted-by":"crossref","first-page":"853724","DOI":"10.3389\/fped.2022.853724","volume":"10","author":"M Jelusic","year":"2022","unstructured":"Jelusic M, Sestan M, Giani T, Cimaz R. New Insights and Challenges Associated with IgA Vasculitis and IgA Vasculitis with Nephritis-Is it Time to change the paradigm of the most common systemic vasculitis in Childhood? Front Pediatr. 2022;10:853724.","journal-title":"Front Pediatr"},{"issue":"4","key":"872_CR6","first-page":"229","volume":"102","author":"BV Reamy","year":"2020","unstructured":"Reamy BV, Servey JT, Williams PM. Henoch-Sch\u00f6nlein Purpura (IgA Vasculitis): Rapid evidence review. Am Fam Physician. 2020;102(4):229\u201333.","journal-title":"Am Fam Physician"},{"issue":"3","key":"872_CR7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.semarthrit.2005.08.007","volume":"35","author":"S Trapani","year":"2005","unstructured":"Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum. 2005;35(3):143\u201353.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"872_CR8","first-page":"31","volume":"118","author":"S G\u00f3mez","year":"2020","unstructured":"G\u00f3mez S, P\u00e9rez M, Pellegrini M, Isern E, Quintana C, Artacho P, et al. Henoch-Schonlein purpura in pediatrics: ten years of experience at a moderate risk office of a general hospital. Arch Argent Pediatr. 2020;118(1):31\u20137.","journal-title":"Arch Argent Pediatr"},{"key":"872_CR9","doi-asserted-by":"crossref","unstructured":"Prais D, Amir J, Nussinovitch M. Recurrent Henoch-Sch\u00f6nlein Purpura in Children. J Clin Rheumatol. 2007;13(1).","DOI":"10.1097\/01.rhu.0000255692.46165.19"},{"issue":"6","key":"872_CR10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/RHU.0b013e31817a240a","volume":"14","author":"A Fretzayas","year":"2008","unstructured":"Fretzayas A, Sionti I, Moustaki M, Papadimitriou A, Nicolaidou P. Henoch-Sch\u00f6nlein purpura: a long-term prospective study in greek children. J Clin Rheumatol. 2008;14(6):324\u201331.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"872_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12969-018-0247-8","volume":"16","author":"W-T Lei","year":"2018","unstructured":"Lei W-T, Tsai P-L, Chu S-H, Kao Y-H, Lin C-Y, Fang L-C, et al. Incidence and risk factors for recurrent Henoch-Sch\u00f6nlein purpura in children from a 16-year nationwide database. Pediatr Rheumatol. 2018;16(1):25.","journal-title":"Pediatr Rheumatol"},{"issue":"1","key":"872_CR12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12969-020-00480-3","volume":"18","author":"C-H Liao","year":"2020","unstructured":"Liao C-H, Tsai M, Yang Y-H, Chiang B-L, Wang L-C. Onset age is a risk factor for refractory pediatric IgA vasculitis: a retrospective cohort study. Pediatr Rheumatol. 2020;18(1):86.","journal-title":"Pediatr Rheumatol"},{"issue":"6","key":"872_CR13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14397595.2019.1687074","volume":"30","author":"RMK Ekinci","year":"2020","unstructured":"Ekinci RMK, Balci S, Melek E, Karabay Bayazit A, Dogruel D, Altintas DU, et al. Clinical manifestations and outcomes of 420 children with Henoch Sch\u00f6nlein Purpura from a single referral center from Turkey: a three-year experience. Mod Rheumatol. 2020;30(6):1039\u201346.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"872_CR14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/adc.2009.167874","volume":"95","author":"O Jauhola","year":"2010","unstructured":"Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, H\u00f6ltt\u00e4 T, et al. Clinical course of extrarenal symptoms in Henoch\u2013Sch\u00f6nlein purpura: a 6-month prospective study. Arch Dis Child. 2010;95(11):871.","journal-title":"Arch Dis Child"},{"issue":"2","key":"872_CR15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000516765","volume":"238","author":"M Sestan","year":"2022","unstructured":"Sestan M, Srsen S, Kifer N, Sapina M, Batnozic Varga M, Ovuka A, et al. Persistence and severity of cutaneous Manifestations in IgA Vasculitis is Associated with Development of IgA Vasculitis Nephritis in Children. Dermatology. 2022;238(2):340\u20136.","journal-title":"Dermatology"},{"issue":"28","key":"872_CR16","doi-asserted-by":"crossref","first-page":"e4217","DOI":"10.1097\/MD.0000000000004217","volume":"95","author":"V Calvo-R\u00edo","year":"2016","unstructured":"Calvo-R\u00edo V, Hern\u00e1ndez JL, Ortiz-Sanju\u00e1n F, Loricera J, Palmou-Fontana N, Gonz\u00e1lez-Vela MC, et al. Relapses in patients with Henoch-Sch\u00f6nlein purpura: analysis of 417 patients from a single center. Med (Baltim). 2016;95(28):e4217\u2013e.","journal-title":"Med (Baltim)"},{"issue":"11","key":"872_CR17","doi-asserted-by":"crossref","first-page":"e0167346","DOI":"10.1371\/journal.pone.0167346","volume":"11","author":"H Chan","year":"2016","unstructured":"Chan H, Tang YL, Lv XH, Zhang GF, Wang M, Yang HP, et al. Risk factors Associated with Renal involvement in Childhood Henoch-Sch\u00f6nlein Purpura: a Meta-analysis. PLoS ONE. 2016;11(11):e0167346.","journal-title":"PLoS ONE"},{"issue":"10","key":"872_CR18","doi-asserted-by":"crossref","first-page":"e0223218","DOI":"10.1371\/journal.pone.0223218","volume":"14","author":"D Shi","year":"2019","unstructured":"Shi D, Chan H, Yang X, Zhang G, Yang H, Wang M, et al. Risk factors associated with IgA vasculitis with nephritis (Henoch-Sch\u00f6nlein purpura nephritis) progressing to unfavorable outcomes: a meta-analysis. PLoS ONE. 2019;14(10):e0223218.","journal-title":"PLoS ONE"},{"issue":"2","key":"872_CR19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1590\/S0021-75572007000200013","volume":"83","author":"CS Alfredo","year":"2007","unstructured":"Alfredo CS, Nunes NA, Len CA, Barbosa CM, Terreri MT, Hil\u00e1rio MO. Henoch-Sch\u00f6nlein purpura: recurrence and chronicity. J Pediatr (Rio J). 2007;83(2):177\u201380.","journal-title":"J Pediatr (Rio J)"},{"issue":"1","key":"872_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00296-004-0452-2","volume":"25","author":"D Rigante","year":"2005","unstructured":"Rigante D, Candelli M, Federico G, Bartolozzi F, Porri MG, Stabile A. Predictive factors of renal involvement or relapsing disease in children with Henoch-Sch\u00f6nlein purpura. Rheumatol Int. 2005;25(1):45\u20138.","journal-title":"Rheumatol Int"},{"issue":"10","key":"872_CR21","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00431-015-2547-z","volume":"174","author":"YL Zhao","year":"2015","unstructured":"Zhao YL, Liu ZJ, Bai XM, Wang YC, Li GH, Yan XY. Obesity increases the risk of renal involvement in children with Henoch-Sch\u00f6nlein purpura. Eur J Pediatr. 2015;174(10):1357\u201363.","journal-title":"Eur J Pediatr"},{"issue":"12","key":"872_CR22","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00467-020-04672-7","volume":"35","author":"HA Dundar","year":"2020","unstructured":"Dundar HA, Pektanc M, Bayram MT, Soylu A, Kavukcu S. Obesity is associated with severe clinical course in children with Henoch-Schonlein purpura. Pediatr Nephrol. 2020;35(12):2327\u201333.","journal-title":"Pediatr Nephrol"},{"key":"872_CR23","unstructured":"Oni L et al. The management of complications associated with IgA vasculitis (Henoch Schonlein Purpura) in children and young people: UKKA; 2023 [Available from: https:\/\/ukkidney.org\/sites\/renal.org\/files\/R1vFINAL_IgA%20vasculitis%20-%20complications220523.pdf."},{"issue":"5","key":"872_CR24","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2009.116657","volume":"69","author":"S Ozen","year":"2010","unstructured":"Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798\u2013806.","journal-title":"Ann Rheum Dis"},{"key":"872_CR25","unstructured":"Collingwood C. Biochemistry Laboratory Handbook 2022. Available from: https:\/\/alderhey.nhs.uk\/application\/files\/8516\/4762\/2842\/Alder_Hey_Biochemistry_Laboratory_Handbook_v2.10.pdf."},{"key":"872_CR26","unstructured":"Department of Haematology AHCsNFT. Haematology and Blood Transfusion Laboratory Handbook 2022. Available from: https:\/\/alderhey.nhs.uk\/application\/files\/5716\/4448\/4397\/Alder_Hey_Haematology_handbook_2022_v1.6.pdf."},{"issue":"1","key":"872_CR27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/03009740510026841","volume":"35","author":"JI Shin","year":"2006","unstructured":"Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Sch\u00f6nlein purpura. Scand J Rheumatol. 2006;35(1):56\u201360.","journal-title":"Scand J Rheumatol"},{"key":"872_CR28","doi-asserted-by":"crossref","unstructured":"Calvino MC, Llorca J, Garcia-Porrua C, Fernandez-Iglesias JL, Rodriguez-Ledo P, Gonzalez-Gay MA. Henoch-Sch\u00f6nlein Purpura in Children from Northwestern Spain: a 20-Year epidemiologic and clinical study. Med (Baltim). 2001;80(5).","DOI":"10.1097\/00005792-200109000-00001"},{"issue":"8","key":"872_CR29","first-page":"14060","volume":"8","author":"M Yan","year":"2015","unstructured":"Yan M, Wang Z, Niu N, Zhao J, Peng J. Relationship between chronic tonsillitis and Henoch-Schonlein purpura. Int J Clin Exp Med. 2015;8(8):14060\u20134.","journal-title":"Int J Clin Exp Med"},{"issue":"9","key":"872_CR30","first-page":"927","volume":"23","author":"DH Yin","year":"2021","unstructured":"Yin DH, Guo YL, Cao TT, Pan CL, Zhao GJ, Hu Y. Effect of animal protein diet on the prognosis of children with Henoch-Sch\u00f6nlein purpura. Chin J Contemp Pediatr. 2021;23(9):927\u201332.","journal-title":"Chin J Contemp Pediatr"},{"issue":"1","key":"872_CR31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12969-021-00569-3","volume":"19","author":"GZ Fan","year":"2021","unstructured":"Fan GZ, Li RX, Jiang Q, Niu MM, Qiu Z, Chen WX, et al. Streptococcal infection in childhood Henoch-Sch\u00f6nlein purpura: a 5-year retrospective study from a single tertiary medical center in China, 2015\u20132019. Pediatr Rheumatol. 2021;19(1):79.","journal-title":"Pediatr Rheumatol"},{"issue":"10","key":"872_CR32","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/0895-4356(93)90117-J","volume":"46","author":"GC Gray","year":"1993","unstructured":"Gray GC, Struewing JP, Hyams KC, Escamilla J, Tupponce AK, Kaplan EL. Interpreting a single antistreptolysin O test: a comparison of the \u201cupper limit of normal\u201d and likelihood ratio methods. J Clin Epidemiol. 1993;46(10):1181\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"2\u20133","key":"872_CR33","first-page":"153","volume":"23","author":"S Wananukul","year":"2005","unstructured":"Wananukul S, Voramethkul W, Kaewopas Y, Hanvivatvong O. Prevalence of positive antinuclear antibodies in healthy children. Asian Pac J Allergy Immunol. 2005;23(2\u20133):153\u20137.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"4","key":"872_CR34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/00325481.2019.1609814","volume":"131","author":"RMK Ekinci","year":"2019","unstructured":"Ekinci RMK, Balci S, Sari Gokay S, Yilmaz HL, Dogruel D, Altintas DU, et al. Do practical laboratory indices predict the outcomes of children with Henoch-Sch\u00f6nlein purpura? Postgrad Med. 2019;131(4):295\u20138.","journal-title":"Postgrad Med"},{"issue":"6","key":"872_CR35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/14397595.2019.1690966","volume":"30","author":"\u015e G\u00f6k\u00e7e","year":"2020","unstructured":"G\u00f6k\u00e7e \u015e, Kurug\u00f6l Z, Koturo\u011flu G, Aslan A. Predictive role of laboratory markers and clinical features for recurrent Henoch-Sch\u00f6nlein Purpura in childhood: a study from Turkey. Mod Rheumatol. 2020;30(6):1047\u201352.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"872_CR36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1179\/146532806X90628","volume":"26","author":"M Cakir","year":"2006","unstructured":"Cakir M, Orhan F, Mungan I, Sonmez FM, Aslan Y, Kalyoncu M, et al. Henoch-Sch\u00f6nlein purpura in north-eastern Turkey. Ann Trop Paediatr. 2006;26(1):59\u201365.","journal-title":"Ann Trop Paediatr"},{"key":"872_CR37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5152\/etd.2013.63","volume":"36","author":"A Y\u0131lmaz","year":"2014","unstructured":"Y\u0131lmaz A, Aytac M, Ekinci Z. Retrospective Assessment of children with Henoch-Schonlein Purpura in and around Kocaeli Province and comparison with literature. Erciyes Med J. 2014;36:62\u20137.","journal-title":"Erciyes Med J"},{"issue":"5","key":"872_CR38","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s10067-017-3972-3","volume":"37","author":"IM Buscatti","year":"2018","unstructured":"Buscatti IM, Casella BB, Aikawa NE, Watanabe A, Farhat SCL, Campos LMA, et al. Henoch-Sch\u00f6nlein purpura nephritis: initial risk factors and outcomes in a latin american tertiary center. Clin Rheumatol. 2018;37(5):1319\u201324.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"872_CR39","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","volume":"58","author":"S Ozen","year":"2019","unstructured":"Ozen S, Marks SD, Brogan P, Groot N, de Graeff N, Avcin T, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford). 2019;58(9):1607\u201316.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"872_CR40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jpeds.2006.03.024","volume":"149","author":"J Ronkainen","year":"2006","unstructured":"Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in Henoch-Sch\u00f6nlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149(2):241\u20137.","journal-title":"J Pediatr"},{"issue":"4","key":"872_CR41","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1542\/peds.2009-3348","volume":"126","author":"PF Weiss","year":"2010","unstructured":"Weiss PF, Klink AJ, Localio R, Hall M, Hexem K, Burnham JM, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Sch\u00f6nlein purpura. Pediatrics. 2010;126(4):674\u201381.","journal-title":"Pediatrics"},{"issue":"1","key":"872_CR42","doi-asserted-by":"crossref","first-page":"e0170259","DOI":"10.1371\/journal.pone.0170259","volume":"12","author":"F Aljebab","year":"2017","unstructured":"Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long-course oral Corticosteroids in Children. PLoS ONE. 2017;12(1):e0170259\u2013e.","journal-title":"PLoS ONE"},{"issue":"1","key":"872_CR43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12969-016-0100-x","volume":"14","author":"L Fotis","year":"2016","unstructured":"Fotis L, Tuttle PVt, Baszis KW, Pepmueller PH, Moore TL, White AJ. Azathioprine therapy for steroid-resistant Henoch-Sch\u00f6nlein purpura: a report of 6 cases. Pediatr Rheumatol. 2016;14(1):37.","journal-title":"Pediatr Rheumatol"},{"issue":"9","key":"872_CR44","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/0009922814568288","volume":"54","author":"T Chou","year":"2015","unstructured":"Chou T, Louissant VR, Adams A, Gurkan S, Chefitz D, Weller AS, et al. Successful treatment of Henoch-Sch\u00f6nlein Purpura with recurrent gastrointestinal involvement with Mycophenolate Mofetil: a brief report. Clin Pediatr. 2015;54(9):900\u20133.","journal-title":"Clin Pediatr"},{"issue":"5","key":"872_CR45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3345\/kjp.2019.00514","volume":"63","author":"KH Lee","year":"2020","unstructured":"Lee KH, Hong SH, Jun J, Jo Y, Jo W, Choi D, et al. Treatment of refractory IgA vasculitis with dapsone: a systematic review. Clin Exp Pediatr. 2020;63(5):158\u201363.","journal-title":"Clin Exp Pediatr"},{"issue":"7","key":"872_CR46","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.autrev.2018.01.016","volume":"17","author":"A Casian","year":"2018","unstructured":"Casian A, Sangle SR, D\u2019Cruz DP. New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis. Autoimmun Rev. 2018;17(7):660\u20134.","journal-title":"Autoimmun Rev"},{"issue":"8","key":"872_CR47","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/ckj\/sfaa251","volume":"14","author":"E Van de Perre","year":"2021","unstructured":"Van de Perre E, Jones RB, Jayne DRW. IgA vasculitis (Henoch\u2013Sch\u00f6nlein purpura): refractory and relapsing disease course in the adult population. Clin Kidney J. 2021;14(8):1953\u201360.","journal-title":"Clin Kidney J"},{"issue":"1","key":"872_CR48","doi-asserted-by":"crossref","first-page":"102707","DOI":"10.1016\/j.autrev.2020.102707","volume":"20","author":"C Rasmussen","year":"2021","unstructured":"Rasmussen C, Tisseyre M, Garon-Czmil J, Atzenhoffer M, Guillevin L, Salem J-E, et al. Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach. Autoimmun rev. 2021;20(1):102707.","journal-title":"Autoimmun rev"},{"issue":"4","key":"872_CR49","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2169\/internalmedicine.38.376","volume":"38","author":"A Kusuda","year":"1999","unstructured":"Kusuda A, Migita K, Tsuboi M, Degawa M, Matsuoka N, Tominaga M, et al. Successful treatment of adult-onset Henoch-Sch\u00f6nlein purpura nephritis with high-dose immunoglobulins. Intern Med. 1999;38(4):376\u20139.","journal-title":"Intern Med"},{"issue":"9","key":"872_CR50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0248-8663(97)83754-X","volume":"18","author":"A Ruellan","year":"1997","unstructured":"Ruellan A, Khatibi M, Staub T, Martin T, Storck D, Christmann D. Purpura rhumato\u00efde et immunoglobulines intraveineuses. Rev Med Interne. 1997;18(9):727\u20139.","journal-title":"Rev Med Interne"},{"issue":"6","key":"872_CR51","first-page":"577","volume":"42","author":"FJ Heldrich","year":"1993","unstructured":"Heldrich FJ, Minkin S, Gatdula CL. Intravenous immunoglobulin in Henoch-Sch\u00f6nlein purpura: a case study. Md Med J. 1993;42(6):577\u20139.","journal-title":"Md Med J"},{"issue":"8","key":"872_CR52","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1093\/rheumatology\/keaa743","volume":"60","author":"F Morotti","year":"2021","unstructured":"Morotti F, Bracciolini G, Caorsi R, Cattaneo L, Gattorno M, Ravelli A, et al. Intravenous immunoglobulin for corticosteroid-resistant intestinal Henoch-Sch\u00f6nlein purpura: worth a controlled trial against corticosteroids? Rheumatology. 2021;60(8):3868\u201371.","journal-title":"Rheumatology"},{"issue":"4","key":"872_CR53","doi-asserted-by":"crossref","first-page":"102490","DOI":"10.1016\/j.autrev.2020.102490","volume":"19","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2020","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Carbonell C, Mir\u00f3n-Canelo JA, Diez-Ruiz S, Marcos M, Chamorro AJ. Rituximab treatment for IgA vasculitis: a systematic review. Autoimmun Rev. 2020;19(4):102490.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"872_CR54","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0036933018809816","volume":"64","author":"R Miray Kisla Ekinci","year":"2019","unstructured":"Miray Kisla Ekinci R, Balci S, Serbes M, Duyuler Ay\u00e7in G, Dogruel D, Ufuk Altintas D, et al. Recurrent Henoch Sch\u00f6nlein purpura without renal involvement successfully treated with methotrexate. Scott Med J. 2019;64(2):74\u20137.","journal-title":"Scott Med J"},{"issue":"6","key":"872_CR55","first-page":"767","volume":"21","author":"P Rettig","year":"2003","unstructured":"Rettig P, Cron RQ. Methotrexate used as a steroid-sparing agent in non-renal chronic Henoch-Sch\u00f6nlein purpura. Clin Exp Rheumatol. 2003;21(6):767\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"872_CR56","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.nurpra.2019.08.014","volume":"15","author":"L Yaxing","year":"2019","unstructured":"Yaxing L, Xia S, Shu L, Zhihong L, Qiaoju Y, Yanwei W, et al. Parents resilience affects Condition of Children with Henoch-Schonlein Purpura Nephritis. J N Pract. 2019;15(10):796\u2013800.","journal-title":"J N Pract"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00872-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00872-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T19:26:08Z","timestamp":1700249168000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00872-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00872-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2831178\/v1","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]},"assertion":[{"value":"1 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Although did study did not require ethical approval, some patients were identified through the IgA Vasculitis Study. The IgAV study was approved by HRA and Health and Care Research Wales (HCRW) on June 21, 2019 (REC 17\/NE\/0390, protocol UoL001347, IRAS 236599). Informed consent was obtained from all subjects (or their parents\/guardians) involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}